AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35437789 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally Informed and Flexible Family Treatment for Adolescents (CIFFTA)
Number of subjects: 200
Study 35437789 — intervention group
Group type: COMPARATOR
Intervention: Individually Oriented Treatment‐As‐Usual (ITAU)
Number of subjects: 200
Study 34044690 — intervention group
Group type: EXPERIMENTAL
Intervention: AutonoMe with Clareon IOL
Number of subjects: 58
Study 34044690 — intervention group
Group type: COMPARATOR
Intervention: iSert with Vivinex IOL
Number of subjects: 58
Study 35674265 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Lim‐Tsai repair technique
Number of subjects: 10
Study 35674265 — intervention group
Group type: COMPARATOR
Intervention: Asymmetric repair technique
Number of subjects: 10
Study 33022293 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (n=69, 62%)
Number of subjects: 112
Study 33022293 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccine (n=12, 11%)
Number of subjects: 112
Study 33022293 — intervention group
Group type: EXPERIMENTAL
Intervention: Numerous antivirals and immune enhancers
Number of subjects: 112
Study 33022293 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-exposure prophylaxis
Number of subjects: 112
Study 33022293 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-exposure prophylaxis
Number of subjects: 112
Study 32252820 — intervention group
Group type: EXPERIMENTAL
Intervention: VWLR2
Number of subjects: 0
Study 32252820 — intervention group
Group type: EXPERIMENTAL
Intervention: SupLR, C, VWLR2, J, LRE, WC
Number of subjects: 0
Study 32252820 — intervention group
Group type: EXPERIMENTAL
Intervention: LRL, VWLR, VWLR2, WC, J
Number of subjects: 0
Study 32252820 — intervention group
Group type: EXPERIMENTAL
Intervention: LR, LRE, VWLR, C, VWLR2, SupLR
Number of subjects: 0
Study 32252820 — intervention group
Group type: COMPARATOR
Intervention: All tests
Number of subjects: 0
Study 32252820 — intervention group
Group type: COMPARATOR
Intervention: Weighted logrank tests
Number of subjects: 0
Study 35690797 — intervention group
Group type: EXPERIMENTAL
Intervention: NEuRoMS intervention plus usual care
Number of subjects: 60
Study 35690797 — intervention group
Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 60
Study 34726270 — intervention group
Group type: EXPERIMENTAL
Intervention: IGAxBSA
Number of subjects: 6518
Study 34726270 — intervention group
Group type: COMPARATOR
Intervention: EASI
Number of subjects: 6518
Study 34726270 — intervention group
Group type: COMPARATOR
Intervention: SCORAD
Number of subjects: 6518
Study 33796955 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine gel with 1% choline geranate
Number of subjects: 0
Study 33796955 — intervention group
Group type: COMPARATOR
Intervention: Caffeine gel without ionic liquid
Number of subjects: 0
Study 35863837 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram based on 12 characteristics (education, professional title, age, burnout, effort-reward imbalance, asbestos dust, hypertension, diabetes, working hours per day, working years, marital status, work schedule)
Number of subjects: 7118
Study 33615506 — intervention group
Group type: EXPERIMENTAL
Intervention: In-center brochure and follow-up email
Number of subjects: 847
Study 33615506 — intervention group
Group type: EXPERIMENTAL
Intervention: Email only
Number of subjects: 847
Study 33615506 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 847
Study 33615506 — intervention group
Group type: EXPERIMENTAL
Intervention: In-center brochure plus email
Number of subjects: 847
Study 32339943 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbopelvic stiffening technique
Number of subjects: 32
Study 32339943 — intervention group
Group type: COMPARATOR
Intervention: Lumbopelvic relaxing technique
Number of subjects: 32
Study 36124526 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 sessions of speech in noise training with a hearing aid
Number of subjects: 20
Study 36124526 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 20
Study 33890579 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning algorithms for detection of myopic macular degeneration
Number of subjects: 226686
Study 33890579 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning algorithms for detection of high myopia
Number of subjects: 226686
Study 33890579 — intervention group
Group type: COMPARATOR
Intervention: Deep learning algorithms compared to six human experts
Number of subjects: 226686
Study 33890579 — intervention group
Group type: EXPERIMENTAL
Intervention: Blockchain technology for data transfer and model testing
Number of subjects: 226686
Study 35067080 — intervention group
Group type: EXPERIMENTAL
Intervention: LIA + continuous postoperative infusion of local anaesthetic for 48 hours
Number of subjects: 108
Study 35067080 — intervention group
Group type: COMPARATOR
Intervention: LIA only (Control Group)
Number of subjects: 108
Study 34031337 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedometer group (PG) - minimum target: 8,000 steps/day; n=36
Number of subjects: 70
Study 34031337 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) - no change in walking; n=34
Number of subjects: 70
Study 32370767 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha/delta neurofeedback training
Number of subjects: 0
Study 32370767 — intervention group
Group type: COMPARATOR
Intervention: Beta/theta neurofeedback training
Number of subjects: 0
Study 32370767 — intervention group
Group type: COMPARATOR
Intervention: Diary control group
Number of subjects: 0
Study 34854157 — intervention group
Group type: EXPERIMENTAL
Intervention: Ion-exchange water softener installed in home
Number of subjects: 80
Study 34854157 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual domestic hard water)
Number of subjects: 80
Study 34616559 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium Bicarbonate
Number of subjects: 118
Study 34616559 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 118
Study 35472097 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy-dense enteral nutrition (1.5 kcal/mL)
Number of subjects: 3876
Study 35472097 — intervention group
Group type: COMPARATOR
Intervention: Standard enteral nutrition (1.0 kcal/mL)
Number of subjects: 3876
Study 35472097 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with GRV ≥250 mL
Number of subjects: 3876
Study 33165151 — intervention group
Group type: EXPERIMENTAL
Intervention: repetitive transcranial magnetic stimulation (rTMS)
Number of subjects: 4
Study 33165151 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS followed by amantadine (rTMS+AMA)
Number of subjects: 4
Study 33165151 — intervention group
Group type: EXPERIMENTAL
Intervention: amantadine (AMA)
Number of subjects: 4
Study 33165151 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS+AMA
Number of subjects: 4
Study 34978021 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapered group (n = 17) - Epoprostenol was resumed after reperfusion and gradually tapered over 2 weeks.
Number of subjects: 23
Study 34978021 — intervention group
Group type: COMPARATOR
Intervention: Discontinued group (n = 6) - Epoprostenol was discontinued after the establishment of extracorporeal circulation.
Number of subjects: 23
Study 32138689 — intervention group
Group type: EXPERIMENTAL
Intervention: CKD stage 4
Number of subjects: 5796
Study 32138689 — intervention group
Group type: COMPARATOR
Intervention: CKD stage 1-2
Number of subjects: 5796
Study 32917418 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased intramuscular adipose tissue of the quadriceps
Number of subjects: 371
Study 32917418 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadriceps echo intensity
Number of subjects: 371
Study 32917418 — intervention group
Group type: EXPERIMENTAL
Intervention: Food Intake Level Scale (FILS)
Number of subjects: 371
Study 32917418 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric Nutritional Risk Index (GNRI) score
Number of subjects: 371
Study 32917418 — intervention group
Group type: EXPERIMENTAL
Intervention: Updated Charlson comorbidity index (UCCI)
Number of subjects: 371
Study 32917418 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous fat thickness of the thigh
Number of subjects: 371
Study 32917418 — intervention group
Group type: EXPERIMENTAL
Intervention: Length of hospital stay
Number of subjects: 371
Study 32917418 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadriceps thickness
Number of subjects: 371
Study 32917418 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 371
Study 32917418 — intervention group
Group type: EXPERIMENTAL
Intervention: Sex
Number of subjects: 371
Study 32917418 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) concentration
Number of subjects: 371
Study 32917418 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of medications
Number of subjects: 371
Study 32068839 — intervention group
Group type: EXPERIMENTAL
Intervention: iDISK knowledge base
Number of subjects: 50
Study 36544075 — intervention group
Group type: EXPERIMENTAL
Intervention: One dose of RBX2660 + one dose of placebo
Number of subjects: 134
Study 36544075 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of RBX2660
Number of subjects: 134
Study 36544075 — intervention group
Group type: COMPARATOR
Intervention: Two doses of placebo
Number of subjects: 134
Study 36544075 — intervention group
Group type: EXPERIMENTAL
Intervention: One dose of RBX2660 + one dose of placebo (per-protocol population)
Number of subjects: 134
Study 36544075 — intervention group
Group type: COMPARATOR
Intervention: Two doses of placebo (per-protocol population)
Number of subjects: 134
Study 36544075 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of RBX2660 (per-protocol population)
Number of subjects: 134
Study 34488363 — intervention group
Group type: EXPERIMENTAL
Intervention: Meticulous nursing model
Number of subjects: 108
Study 34488363 — intervention group
Group type: COMPARATOR
Intervention: Conventional nursing
Number of subjects: 108
Study 32871704 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label placebo (OLP) treatment for 8 weeks (n = 18)
Number of subjects: 38
Study 32871704 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU) for 4 weeks followed by OLP for 4 weeks (n = 20)
Number of subjects: 38
Study 32871704 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall group comparison
Number of subjects: 38
Study 32871704 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-geriatric patients (<65 years) with early onset depression (<50 years)
Number of subjects: 38
Study 36166095 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromagnetically (EM) navigated TKA
Number of subjects: 199
Study 36166095 — intervention group
Group type: COMPARATOR
Intervention: Conventional TKA
Number of subjects: 199
Study 32579152 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic knowledge
Number of subjects: 189
Study 32579152 — intervention group
Group type: EXPERIMENTAL
Intervention: Current communication of CRC risk
Number of subjects: 189
Study 32634485 — intervention group
Group type: EXPERIMENTAL
Intervention: Resilient Youth with NF (RY-NF)
Number of subjects: 200
Study 32634485 — intervention group
Group type: COMPARATOR
Intervention: Health Education for NF (HE-NF)
Number of subjects: 200
Study 35109905 — intervention group
Group type: EXPERIMENTAL
Intervention: ALPS-PHP plate with pegs
Number of subjects: 110
Study 35109905 — intervention group
Group type: COMPARATOR
Intervention: PHILOS plate with screws
Number of subjects: 110
Study 34132703 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative monotherapy with PT
Number of subjects: 162
Study 34132703 — intervention group
Group type: COMPARATOR
Intervention: Standard 2-drug therapy with CM
Number of subjects: 162
Study 32557923 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine dosage of 175 μg/kg/min
Number of subjects: 100
Study 32557923 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine dosage of 210 μg/kg/min
Number of subjects: 100
Study 32557923 — intervention group
Group type: COMPARATOR
Intervention: Adenosine dosage of 140 μg/kg/min
Number of subjects: 100
Study 32557923 — intervention group
Group type: COMPARATOR
Intervention: Comparison of groups 2 and 3 vs group 1
Number of subjects: 100
Study 32557923 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3 (210 μg/kg/min)
Number of subjects: 100
Study 35729713 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozoralizumab 30 mg plus MTX
Number of subjects: 381
Study 35729713 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozoralizumab 80 mg plus MTX
Number of subjects: 381
Study 35729713 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus MTX
Number of subjects: 381
Study 34533430 — intervention group
Group type: EXPERIMENTAL
Intervention: ACHIEVE hearing intervention
Number of subjects: 0
Study 33766818 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin with upfront dexrazoxane
Number of subjects: 33
Study 33766818 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin alone (historical control)
Number of subjects: 33
Study 35973803 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 million IU/day of subcutaneous IL-2 (ILT-101) for 5 days followed by weekly injections for 12 weeks
Number of subjects: 100
Study 35973803 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 35973803 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 million IU/day of subcutaneous IL-2 (ILT-101)
Number of subjects: 100
Study 33356028 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 950
Study 33356028 — intervention group
Group type: COMPARATOR
Intervention: Calcineurin inhibitor (CNI)
Number of subjects: 950
Study 32310288 — intervention group
Group type: EXPERIMENTAL
Intervention: Mammography Screening Decision Aid (DA)
Number of subjects: 546
Study 32310288 — intervention group
Group type: COMPARATOR
Intervention: Control arm (Home Safety pamphlet)
Number of subjects: 546
Study 35120174 — intervention group
Group type: EXPERIMENTAL
Intervention: MedicineWise app + usual care
Number of subjects: 55
Study 35120174 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 55
Study 34327879 — intervention group
Group type: EXPERIMENTAL
Intervention: NT‐proBNP measurements in newborns with CHD
Number of subjects: 126
Study 34327879 — intervention group
Group type: EXPERIMENTAL
Intervention: NT‐proBNP measurements in newborns with combined heart defects
Number of subjects: 126
Study 36163838 — intervention group
Group type: EXPERIMENTAL
Intervention: Enasidenib 100 mg/day
Number of subjects: 319
Study 36163838 — intervention group
Group type: COMPARATOR
Intervention: Conventional Care Regimens (CCR)
Number of subjects: 319
Study 33289297 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotagliflozin 200 mg
Number of subjects: 0
Study 33289297 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotagliflozin 400 mg
Number of subjects: 0
Study 33289297 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32379288 — intervention group
Group type: EXPERIMENTAL
Intervention: Facedown positioning for 8 hours daily for 5 days
Number of subjects: 185
Study 32379288 — intervention group
Group type: COMPARATOR
Intervention: Face forward positioning for 8 hours daily for 5 days
Number of subjects: 185
Study 32379288 — intervention group
Group type: EXPERIMENTAL
Intervention: Facedown positioning
Number of subjects: 185
Study 32379288 — intervention group
Group type: COMPARATOR
Intervention: Face forward positioning
Number of subjects: 185
Study 34915982 — intervention group
Group type: EXPERIMENTAL
Intervention: Mavacamten
Number of subjects: 251
Study 34915982 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 251
Study 36401234 — intervention group
Group type: COMPARATOR
Intervention: Daily calcium citrate 600 mg (control group)
Number of subjects: 34
Study 33402404 — intervention group
Group type: EXPERIMENTAL
Intervention: Burnaid hydrogel dressing
Number of subjects: 72
Study 33402404 — intervention group
Group type: COMPARATOR
Intervention: Plasticised polyvinylchloride film (Control)
Number of subjects: 72
Study 33941193 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-rated health after reporting bodyweight (treatment group)
Number of subjects: 2523
Study 33941193 — intervention group
Group type: COMPARATOR
Intervention: Self-rated health before reporting bodyweight (control group)
Number of subjects: 2523
Study 32996693 — intervention group
Group type: EXPERIMENTAL
Intervention: Data-driven machine-learning model
Number of subjects: 0
Study 32996693 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple hypoglycaemia risk score
Number of subjects: 0
Study 32996693 — intervention group
Group type: EXPERIMENTAL
Intervention: Both models
Number of subjects: 0
Study 33990478 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-aortic balloon pump preoperatively in high-risk patients awaiting coronary artery bypass grafting
Number of subjects: 0
Study 33990478 — intervention group
Group type: EXPERIMENTAL
Intervention: Impella as part of an early MCS strategy in CS
Number of subjects: 0
Study 33990478 — intervention group
Group type: EXPERIMENTAL
Intervention: ECMO facilitated resuscitation
Number of subjects: 0
Study 32008789 — intervention group
Group type: EXPERIMENTAL
Intervention: Total space available per cow
Number of subjects: 53
Study 32008789 — intervention group
Group type: EXPERIMENTAL
Intervention: Living space per cow
Number of subjects: 53
Study 32008789 — intervention group
Group type: EXPERIMENTAL
Intervention: Farmer opinions on loafing space
Number of subjects: 53
Study 32008789 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear model predicting living space
Number of subjects: 53
Study 35609139 — intervention group
Group type: EXPERIMENTAL
Intervention: Hematic antegrade repriming (HAR)
Number of subjects: 115
Study 35609139 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 115
Study 34262557 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (400 IU daily)
Number of subjects: 62
Study 34262557 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 34269705 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational intervention based on the 5 R's model delivered by specialized inflammatory bowel disease nurses every 3 months over a 1‐year period
Number of subjects: 144
Study 34269705 — intervention group
Group type: COMPARATOR
Intervention: Regular follow-up (Control)
Number of subjects: 144
Study 32008784 — intervention group
Group type: EXPERIMENTAL
Intervention: Bale cutting engagement (cut)
Number of subjects: 24
Study 32008784 — intervention group
Group type: EXPERIMENTAL
Intervention: Orchardgrass
Number of subjects: 24
Study 35674120 — intervention group
Group type: EXPERIMENTAL
Intervention: Instrument-assisted soft tissue mobilization (IASTM)
Number of subjects: 72
Study 35674120 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure algometry
Number of subjects: 72
Study 35674120 — intervention group
Group type: COMPARATOR
Intervention: Sham ultrasound (control group)
Number of subjects: 72
Study 33518708 — intervention group
Group type: EXPERIMENTAL
Intervention: Serotonin depletion (tryptophan depletion)
Number of subjects: 73
Study 33518708 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 73
Study 37344086 — intervention group
Group type: EXPERIMENTAL
Intervention: Quercetin (500 mg/day)
Number of subjects: 88
Study 37344086 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 33879453 — intervention group
Group type: EXPERIMENTAL
Intervention: Total testosterone levels (observational analysis)
Number of subjects: 333530
Study 33879453 — intervention group
Group type: EXPERIMENTAL
Intervention: Sex hormone-binding globulin (SHBG) levels (observational analysis)
Number of subjects: 333530
Study 33879453 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone levels (Mendelian randomization analysis)
Number of subjects: 333530
Study 33879453 — intervention group
Group type: EXPERIMENTAL
Intervention: Free testosterone levels (observational and MR analyses)
Number of subjects: 333530
Study 35842106 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted clinical pharmacy intervention (medication reconciliation at admission and discharge, medication review, patient/caregiver education, intensified communication with primary care providers, post-discharge follow-up including telepharmacology service)
Number of subjects: 828
Study 35842106 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 828
Study 35842106 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted clinical pharmacy intervention
Number of subjects: 828
Study 33475710 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular use of aspirin
Number of subjects: 94540
Study 33475710 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular use of aspirin initiated before age 70 years
Number of subjects: 94540
Study 33475710 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular use of aspirin initiated at or after age 70 years
Number of subjects: 94540
Study 32291508 — intervention group
Group type: EXPERIMENTAL
Intervention: Indocyanine green (ICG) fluorescence angiography
Number of subjects: 131
Study 32291508 — intervention group
Group type: COMPARATOR
Intervention: Non-ICG group
Number of subjects: 131
Study 32896447 — intervention group
Group type: COMPARATOR
Intervention: Normal glycaemic control (NGC)
Number of subjects: 160
Study 32896447 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired glycaemic control (IGC)
Number of subjects: 160
Study 33273351 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Number of subjects: 164
Study 33273351 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple bupivacaine
Number of subjects: 164
Study 33273351 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 164
Study 34108079 — intervention group
Group type: COMPARATOR
Intervention: LX9211 (single ascending dose)
Number of subjects: 146
Study 34108079 — intervention group
Group type: COMPARATOR
Intervention: LX9211 (multiple ascending dose)
Number of subjects: 146
Study 34108079 — intervention group
Group type: COMPARATOR
Intervention: LX9211 (200 mg cohort)
Number of subjects: 146
Study 34108079 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146
Study 32954715 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive respiratory volume monitor (RVM)
Number of subjects: 50
Study 32954715 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 50
Study 36084153 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional sodium stibogluconate (SSG), administered weekly for a maximum of six doses.
Number of subjects: 83